From the clinic to the capital markets, here is Psychedelic Invest's roundup of the key headlines for the week of May 4–10, 2026.
Lykos Therapeutics: FDA publicly releases Lykos' MDMA complete response letter
The FDA published the previously confidential complete response letter it issued to Lykos Therapeutics in 2024 for MDMA-assisted therapy in PTSD, part of a release of 89 unpublished CRLs under a new transparency policy. The letter detailed concerns including high rates of prior MDMA use among trial participants and screening issues, and it reiterated the agency's request for an additional Phase 3 study. The disclosure sharpened public understanding of the regulatory bar facing MDMA and the broader psychedelic field.
Source: psychedelicalpha.com
Compass Pathways plc (CMPS): Compass sets May 13 date for first-quarter 2026 results
Compass Pathways announced it would report first-quarter 2026 financial results and business highlights on May 13, 2026. The scheduling notice came as investors awaited an update on the company's rolling NDA progress and cash position following its priority-voucher designation. It set up one of the more closely watched psychedelic earnings prints of the quarter.
Source: biospace.com
That's the recap. Follow the Psychedelic Invest Index for how the sector is trading, and check back next week for the next edition.